Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
1 competing product in clinical development for Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy.
Pipeline by Phase
Phase 21
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| OSI-906 + erlotinib + placebo | Astellas Pharma | Phase 2 | Completed | 35 |